New NHL Therapy Moves into Phase III Clinical Trial   1 comment

GSK logoThe international pharmaceutical and healthcare company GlaxoSmithKline is now moving into the phase III clinical trial for a new combination therapy to treat NHL, according to an article by Zenopa. The two drugs that will be combined in this treatment program are ofatumumab and bendamustine.

This new therapy is specifically for indolent B-cell non-Hodgkin’s lymphoma patients. According to Zenopa, this is a form of NHL that is prone to relapse. Traditionally, indolent B-cell NHL patients are treated with rituximab. Now, for those who do not respond to rituximab, GlaxoSmithKline‘s new combination therapy may be the answer.


Posted September 24, 2010 by lymphomactivist in Uncategorized

One response to “New NHL Therapy Moves into Phase III Clinical Trial

Subscribe to comments with RSS.

  1. Me and my colleagues authored one of India’s most extensive reports on clinical trials. Drop me a mail if you are interested in a copy. My email is

    Some of the topics we included are:

    – Market Trends
    – Growth Drivers
    – Regulatory Bodies and Framework
    – Major Players.
    We interviewed over 200 individuals and firms to collect the data in what we believe is one of the most detailed study on the subject in India.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: